about
Toxicity testing in the 21st century: a vision and a strategyFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentReal time dynamic imaging and current targeted therapies in the war on cancer: a new paradigmTargeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabIn vivo imaging demonstrates a time-line for new vessel formation in islet transplantationVascular damage and anti-angiogenic effects of tumor vessel-targeted adenovirus-mediated herpes simplex virus thymidine kinase gene.Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancerDoes volume perfusion computed tomography enable differentiation of metastatic and non-metastatic mediastinal lymph nodes in lung cancer patients? A feasibility studyEffect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.In vivo magnetic resonance imaging of vascularization in islet transplantationHeat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma modelMolecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapyCorrelations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancerMalignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Retrospective Cohort Study.Antiangiogenic therapy in human gastrointestinal malignancies.A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.Inhibiting kinases in malignant gliomas.Inhibition of angiogenesis and invasion in malignant gliomas.The role of clinical imaging in oncological drug development.Anti-VEGF therapy: the search for clinical biomarkers.An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review.Jewel of the seabed: sea cucumbers as nutritional and drug candidates.Predicting lymph node metastasis in patients with papillary thyroid carcinoma by vascular index on power Doppler ultrasound.Can increased tumoral vascularity be a quantitative predicting factor of lymph node metastasis in papillary thyroid microcarcinoma?Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2.Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization.Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging.Optical molecular imaging approach for rapid assessment of response of individual cancer cells to chemotherapy.Ultrasound contrast-enhanced study as an imaging biomarker for anti-cancer drug treatment: preliminary study with paclitaxel in a xenograft mouse tumor model (secondary publication).Correlation between angiogenesis and islet graft function in diabetic mice: magnetic resonance imaging assessment.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging.PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
P2860
Q27921848-C77E05A8-7A29-4FFD-887D-94BEEF2FBBF2Q28533949-06085B9C-A9C7-478A-B71B-E70EF64D4D7FQ30453423-260B531B-6938-4E92-BC9D-3BB413A1FBFBQ33418562-BA274C64-B2B7-42DA-B1A1-4B3C0D939CE2Q33723356-1339E3C4-FD12-4716-807E-F0A6108E94F8Q34224929-28898C16-8840-4C9B-9002-2D394F3A7164Q34390068-CE84CB7E-A5EF-4443-8A9B-9BC8C2D859E3Q34857438-6D776BD7-D78A-4445-8717-A0711C8696E2Q35926256-829396E1-BAC6-4CF3-B88F-099D12945074Q36072776-45ACB7A8-EBB0-4C1E-918C-F9623F261F90Q36168739-1F3E5AD2-C900-4381-8DCC-7EF19A0DE350Q36187025-109C7FCB-9B46-43A0-94C9-B58A50F0DF9EQ36295224-78788F50-CFCF-4E6E-8127-3AA82485376EQ36297117-A47EBD53-185E-4145-85BB-1F1771AA9C59Q36463853-B63980BC-EA60-4609-AA5B-7C972AF56B43Q36499234-38F32E58-E688-4106-8BAE-5BCF5DC77CACQ36580868-1EB9BA38-74BB-432F-9713-6B93D4CE2B6EQ36591067-0A5ECB17-139D-416A-98EC-394D4F87C927Q36614213-62D74882-F236-49A6-B2B6-85CCF995A3E0Q36653663-4C94BD6E-04AD-47A6-8E34-3FFE4CEF5088Q36668246-9BCE38A4-390F-4BF4-ACDB-B5E67705C767Q36764876-B74C7825-1FAB-4572-B258-8BAB96D4FBFCQ37004664-5C131C8B-5300-43DA-B20A-79B0AAD3BCDDQ37187098-15DE2BAD-D2DA-43A1-8F5B-671958F2E3D3Q37206167-50FB4F16-7EC4-49D5-B38D-0E35E20BE6D9Q37337722-AB04E3BB-A2A2-4A1F-B7B6-A212212199BDQ37589551-4A50DA7F-F9B1-4640-BB02-D56FC4253E14Q37871859-4FF7D5B8-31CC-4589-A015-9B8FD36BF55AQ37965731-F507F9D2-9225-44F8-8434-9FF93AB436C3Q38410144-F9DFDE8F-9D94-406A-9370-53D76E420355Q38443234-AEC1CCD6-ED70-4670-B89D-0E05446CD382Q39809361-E285F7A0-B199-4E82-9E32-D72BE45D05F8Q40334510-7D41C78E-E435-4719-92F2-439CC54B8821Q41966656-83B8A892-8C75-484E-AE70-6DF149CBE5A3Q42053570-259A5725-30F9-4C3B-ADDE-A9EC2B89E165Q42367599-643191D4-4D12-4A80-8B65-FD39446E469EQ42939982-DDABAAB9-1308-45CF-AAD9-9D58D1564899Q44491240-8A392037-DB80-41D1-BF8E-D24BCF0D573EQ45943928-F54C5249-16FA-46E6-A91D-F526205184F7Q46897347-2EF54778-2161-4661-8AAC-80B5D49E8366
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Molecular imaging of antiangiogenic agents.
@ast
Molecular imaging of antiangiogenic agents.
@en
type
label
Molecular imaging of antiangiogenic agents.
@ast
Molecular imaging of antiangiogenic agents.
@en
prefLabel
Molecular imaging of antiangiogenic agents.
@ast
Molecular imaging of antiangiogenic agents.
@en
P1433
P1476
Molecular imaging of antiangiogenic agents
@en
P2093
Shazza Rehman
P304
P356
10.1634/THEONCOLOGIST.10-2-92
P577
2005-02-01T00:00:00Z